Latest News



August 30, 2018 0

The latest chapter in the ebook, Modern Marketing: Pharma's Data-Powered AI Revolution, was released this Tuesday by Intouch Solutions and Digital Health Coalition. Chapter 4, Ask the Experts: The Pharma POV, revealed that “there are significant shifts away from AI being ‘not an issue today' to ‘becoming very important' in 2019” as 38% of respondents ranked AI as “very important” for 2019 (vs 25% for 2018). Perhaps more tellingly, just a mere “8% of pharma executives rank AI as having very low importance for 2019 – down from 21% in 2018.”

The surveys conducted found that while pharma is still learning about AI and all it has to offer, some are already using AI for marketing (26%) or plans to use it are underway (30%). As the ebook noted, while companies would logically not chase every fad technology, “the greatest potential driver of future (or continued) investment in AI is … better customer insight.” Of the pharma executives surveyed, 17% are already reported a measurable value regarding better customer insights. “Beyond that, the second area is automating routine business processes (14%), following by increased efficiency (8%), and improving customer satisfaction (8%).”

Click here to access a copy of the ebook, which shares additional survey results, insights, and interviews with industry KOLs.

admin


August 30, 2018 0

Novo Nordisk launched a branded DTC campaign for Ozempic, a once-weekly GLP-1 injectable prescription for adults with type 2 diabetes that, along with diet and exercise, may improve blood sugar. The national TV spot is set to the catchy 1970s song, “Magic” by Pilot – but uses altered lyrics to educate consumers about the treatment, as well as its risks and benefits. According to the news release, the commercial “portrays typical people living with type 2 diabetes who are working to meet their treatment goals, while participating in everyday activities,” such as a firefighter at his station interacting with community members; a farmer helping a couple picking fruit and vegetables; and a woman visiting an indoor conservatory with her family. The 90-second ad, which shows the actors replying “Oh!” to the same beat of the song as they learn something new about Ozempic, premiered on August 1st.

Ozempic's campaign is also supported with a print ad and website. The brand received FDA approval in December 2017 for adults with type 2 diabetes, and along with diet and exercise, may improve blood sugar.

admin


August 29, 2018 0

As Peter Drucker, renowned educator, management consultant, and author, said, “The aim of marketing is to know and understand the customer so well the product or service fits him and sells itself.” This mantra holds true with multicultural marketing in the pharmaceutical industry, especially with Hispanic and Latino populations. Successful pharmaceutical marketing amongst the Spanish groups should focus on providing personalized care to the right individual at the right time in the right place thereby expanding upon the basic tenet of the Affordable Care Act which reaches all Americans.

Below are a few cultural considerations that increase industry profits by positively impacting the development of strategies for pharma marketing to Hispanic and Latino consumers who experience customized care.

Family Dynamics vs. Individualism

  • Group interdependence among family is at the center of the Hispanic world. Affiliation, cooperation, and group activities are weighted heavily as Latinos understand there is strength in numbers. Their health decisions rely on an extended family model and are typically made after consulting various family members. Opinions from adult children of the older generation are valued extensively. Pharma branding with marketing campaigns needs to be family-focused.

Imagery vs. Text

  • In the Hispanic culture, a picture is worth a thousand words. Incorporating culturally embedded cues into pharma marketing that reflect attire, family values, symbols, ethics, rituals, traditions, material objects, and services in their culture, stimulate how these consumers respond to the pharma industry. Through this identification process both their self-image and confidence in pharma’s judgment of prescription medication is enhanced, resulting in a change in their attitude towards the brand and eventual increased brand acceptance.

Technology Media vs. Traditional Media

  • In the past, it was widely believed that the only effective way to deliver Spanish-language pharma marketing messages was through traditional media, such as the television networks Telemundo and Univision. However, the newer generation of Hispanics on the go are not as interested in traditional media; they are more interested in smart phone technology and social media sites. One in three are the primary pharma decision makers as caregivers of an older generation of family household members and make their choices by engaging with technology media. They are three times more likely to use their smart phones to decide about pharma for themselves and other family members. Pharma marketing via technology media will soon become a leading strategy that is mandatory.

Fatalism vs. Optimism

  • Many Latinos believe that destiny is predetermined and little can be done to change outcomes. For example, they may believe that death is inevitable after receiving a cancer diagnosis and also believe that any type of prescription drug cannot improve the chance of survival because it is out of their control. A Hispanic participant in a recent NIH study sorrowfully stated, “I worked with a person who had arthritis and was going to get cortisone but the last time she went to get it at the hospital, she didn't return home. Instead, she went to the cemetery.” Pharma marketing must help Hispanics move beyond this mindset by reinforcing examples of positive outcomes in their culture with marketing campaigns targeted at patient support groups on social media, such as Facebook, that encourage pharmaceutical use to recover from an illness.

Natural Healing Remedies vs. Prescriptions

  • Home remedies tend to be the first medicinal approach used in the Latino culture prior to visiting a medical professional. However, often times these home remedies are more detrimental than beneficial. For example, recently Hispanic parents treated their infant with star anise tea to cure colic, which resulted in the infant suffering from seizures and needing to be rushed to the emergency room at a Miami hospital. Pharma marketers should see this as a new opportunity to gain market share by targeting Latino consumers with public service announcements about the dangers of consuming natural healing remedies in lieu of advanced pharma medications with proven results.

High Power Distance vs. Low Power Distance

  • Pharma marketing in the Spanish culture is impacted by high power distance because Hispanics conform to a hierarchy where everybody has a place in the world which needs no further justification. On the other hand, in a low power distance culture, inequalities of power between doctor and patient require further justification for acceptance. For example, when doctors prescribe a certain brand of medication to Latinos, often times the pharmaceutical is not questioned since the doctor is viewed as an authority figure not to be doubted for fear of appearing disrespectful. Pharma companies may gain a competitive advantage by providing guides to Hispanic patients describing the brand’s impact and side effects in plain, simple, straightforward, 3rd grade level Spanish language for additional motivational encouragement to stay on a medication regimen with a specific brand.

In summary, minorities are increasingly becoming the new majority and the so-called “average” pharma consumer is now interacting on a complex and multidimensional landscape. Knowing the customer is most likely the single most important concept of a flourishing pharma market across cultures, and in particular with the Hispanic and Latino groups. This growing diversity has had a substantial economic impact as shown by an increase in pharma spending power that has significantly encouraged marketers to take into account various cultural characteristics when formulating a winning marketing strategy.

 

Resources

Barker, KK and Guzman, CEV. Pharmaceutical direct-to-consumer advertising and US Hispanic patient-consumers. Sociology of Health & Illness. 2015 Nov; 37(8):1337-51. doi: 10.1111/1467-9566.12314. Epub 2015 Aug 3.

Katz JN, Lyons N, Wolff LS, et al. Medical decision-making among Hispanics and non-Hispanic Whites with chronic back and knee pain: A qualitative study. BMC Musculoskeletal Disorders. 2011;12:78. doi:10.1186/1471-2474-12-78.

Pinedo, Diana. (2018). The state of multicultural marketing in 2018. Healthcare Success.

Multicultural marketing: Embrace the New Normal. (2016). PM360 Online.

The Case for Culturally Competent Health Marketing. (2016). Newlink America.

admin


August 29, 2018 0

Sponsored Content

Confused about point-of-care (POC) validation measures? I’m not surprised. The transparency and accountability of the POC channel remains a hot topic in the media; some are even calling POC one of the most misunderstood media spaces. I understand why, given every point of view  seems to report on a different “must-have” approach.

While there is no one right approach to POC validation, the bottom line is clear: It all comes down to trust and delivery. When choosing a POC provider to partner with, you not only have to ask whether you can trust the experience of this provider, but also whether they can substantiate with facts that you are indeed getting what you pay for.

Here's a brief overview of the checks and balances PatientPoint® uses to guarantee client deliverables and ensure that trust remains at the center of all our client relationships.

Confirming the Reach is Real

There are two key components to reach verification: providing clients with a list of installed locations and healthcare professionals they are being billed for, and confirming that the POC program purchased is physically there and on. Every brand or agency has the right to this vital information.

PatientPoint has selected SK&A (now IQVIA) as its official arbiter for physicians practicing in a given location. SK&A contacts practices a minimum of every six months to refresh its database. PatientPoint also has a direct line of communication with SK&A to reconcile practice and provider data that doesn’t align. This ensures the most accurate and current data is sent to our clients at all times.

While PatientPoint has been doing physical audits for years, we’ve further elevated our standards, having SPAR and PlaceBridge/J. Knipper take our entire list of installed offices and conduct a physical in-person audit across a statistically valid sample. As an additional action step, we also have the Alliance for Audited Media (AAM) certify the digital device counts we provide to our client partners.

Digital confirmation of device counts across 100% of our installed offices + physical audit verification = information you can trust.

Delivering the Data Behind Your Digital Ad Play

PatientPoint has invested significant capital into a digital signage platform that enables us to capture and track every client ad played in a physician’s office – even if the content is cached. That’s not an easy feat, and we’re proud of our efforts to ensure this can happen. AAM certifies our digital ad play reports we share with clients, and our platform also supports API integration, allowing access to and integration with third parties designated by our agencies or clients.

Validating Script Volume

PatientPoint pioneered the evaluation of POC using script lift data versus CPMs more than 15 years ago. We meet upfront with client research experts to gain alignment on methodology before executing a campaign study. While Symphony is our primary supplier, we have also worked with IMS and Crossix to evaluate our programs. To avoid any concerns surrounding manipulation of results, Symphony can forward results directly to clients and participate in meetings on results of PatientPoint programs.

Moving the Industry Forward

This is just an overview of the standards PatientPoint has in place to ensure clients’ trust and confidence remain in not only PatientPoint, but the entire POC channel. While news about POC transparency and accountability will continue to surround those companies trying to make up time for breach of trust, PatientPoint will demonstrate and deliver the reach and results we’ve always said we would. There’s a saying that it takes years to build up trust and only one moment to lose it. I’ve never forgotten that, and neither has PatientPoint.

I welcome the opportunity to speak with you personally regarding PatientPoint or all things point of care. Please connect with me at linda.ruschau@patientpoint.com or (513) 936-3549.

Linda Ruschau


July 30, 2018 0

The American public's trust level in pharmaceutical companies fell 13%, dropping down to 38% in 2018 compared to 2017, accord to Edelman's recently released Edelman Trust Barometer. According to the report, the “pharma industry [is being] blamed for high cost of drugs and aggressive marketing of opioids as addiction reaches epidemic levels”.

Steve Weiss, Senior Vice President at Edelman, writes on Edelman's website that “This makes pharma companies the least-trusted healthcare industry in the U.S., far lower than hospitals/clinics (70% trust), consumer health (56%), biotech/life sciences (55%) and insurance (46%).” One way to combat this, Weiss suggests, is by partnering with advocacy groups. Such partnerships will add to credibility, especially if the advocacy group is a member of the National Health Council, which has a stringent set of accountability and ethical standards.

Weiss also advises to increase transparency – starting with research and drug development to financial / funding situations, all the way through to content development and article authors, editors, and reviewers. Globally speaking, the general public were more trusting of a pharmaceutical company “if it also provided information, tools, and support to help [patients] manage [their] disease.”

Click here to read the full 2018 Edelman Trust Barometer report.

admin


July 27, 2018 0

The theme of this month’s newsletter is consumer trends. Here’s a recent one worth talking about: According to new research, consumer trust in pharma has hit a new low, dropping 13 points from 51% to 38%.

How can an industry that does so much good have such low credibility? Listen to patient testimonials in focus groups and those that are seeking treatment are incredibly appreciative of their prescribed treatment — especially when it allows them to breathe easier, or control their sugar levels, or prevent a heart attack. So why the drop? According to the research, the high cost of healthcare was partly to blame. Most respondents also said they believed pharma companies put profits ahead of patients.

This latter sentiment uncovers a real need for pharma brands to discover new, more personal ways to connect with patients. 68% of consumers said they would trust a pharma company more if it also provided them with information, tools, and support to help them manage their disease.

So let’s give the patients what they want! This doesn’t require a complete overhaul of your current marketing strategy; rather, brands can identify the right engagement opportunities where refined messaging will resonate most with patients — both inside the physician’s office and out. Promote the patient savings programs to make your drug affordable; explain the how and why of how your drug works in easy-to-understand terms (if regulatory will allow you!).

Putting the focus on the patient first, offering information, and resources throughout his or her care journey that helps them better understand their own condition, more effectively talk to their doctor and more easily find and follow the right treatments, is exactly what is needed to start to turn this trend around.

Point-of-care platforms are already providing patients and caregivers with disease-specific education and information in the waiting room, exam room, and beyond. Take advantage of these channels and feature accompanying content to show you empathize with patients and are truly a trusted partner in their care.

While trends are transitory, we can’t afford to ignore these perceptions of our industry. We all know the good work we’re doing to help patients live better, healthier lives. This research, however, should serve as an important reminder that we could be doing even more to show patients that their best interests are truly at the center of everything we do.

Linda Ruschau


July 27, 2018 0

Whether you’re new to the DTC pharma space in the US, or an industry veteran, what you need to know to stay ahead.

The advertising of prescription drugs on TV and in magazines is a uniquely American phenomenon. Turn on the news or flip through a magazine and you’re likely to notice a pharmaceutical commercial or ad. In fact, prescription drugs are now among the top 10 most advertised product categories in the US.

In the 15 years I’ve helped pharma brands forecast and test their direct-to-consumer (DTC) ad campaigns, I’ve seen a shift in the content. Where ads originally focused on drugs for widespread medical conditions (e.g. high cholesterol, depression), today’s campaigns address health problems suffered by much smaller populations, such as Crohn’s Disease and lung cancer. But that’s just one example of how the DTC pharma market has evolved in the US.

My SKIM healthcare colleagues and I recently attended the DTC National Conference in Boston to explore the industry’s latest trends and innovations. Here I’m sharing our top three takeaways from the DTC conference:

1. The Promise & Pitfalls of the 6-Second DTC Ad

Often referred to as “bumper ads,” the 6-second YouTube ad is a popular option for consumer marketers. But can these work for pharma brands? With their long length, complex messages, and side effects requirements, pharma DTC commercials may seem like unlikely candidates for this media.

However, 6-second DTC ads are not only plausible; their utilization is expected to grow. While the 6-second length is prohibitive for branded DTC ads with product claims and side effects, “reminder ads” are compatible with this short format.

What’s the ideal scenario for this type of media buy?

Woman on tablet

Since reminder ads only emphasize the drug brand name and contain no information about product benefits or side effects, we recommend their use in supplementing larger, branded campaigns. Brands spending at least $50 million in annual advertising will see most success with bumper ads. Since these 6-second ads typically employ the same creative look and feel as the longer commercials, they can aid viewer recall. However, without that level of ad spend, these 6-second DTC reminder ads are risky as they lack context and meaning when they’re seen by patients who haven’t been reached by the associated branded campaign.

2. Consider Addressable TV for Advanced Targeting

Successfully targeting and reaching the intended audience has always been a challenge for pharma marketers planning DTC campaigns. The population of patients who are eligible for the medication may be relatively small, meaning that a high percentage of advertising impressions are “wasted” on viewers who have no interest in the advertised product and will never be candidates for treatment.

“Addressable TV” is a digital innovation that allows marketers to target specific households using algorithms based on demographic and geographic data, similar to digital video. With nearly 50 million US households ‘addressable’ via cable set-top boxes, advertisers can now identify those homes whose members have a greater likelihood of having the medical condition that is treated by their pharmaceutical product.

Couple watching TV

Take as an example osteoarthritis, a medical condition that primarily affects an older demographic. Marketers can use Addressable TV to advertise an osteoarthritis drug directly to households with individuals 60+ years old vs. those with younger viewers who may be tuned in to the same programming next door.

When we work with pharma brands to forecast the impact and ROI of DTC campaigns, we model the awareness-generating ability of Addressable TV differently than we model traditional television. Current industry analysis indicates that Addressable TV is more effective; we will see if this trend remains evident as more and more data becomes available.

3. Explore Ad Concepts with Real Patients vs. Actors to Enhance Campaign Authenticity

Pharmaceutical DTC campaigns are sometimes criticized for using actors who don’t resemble actual patients, presenting an unrealistic depiction of the medical condition. Perhaps with this criticism in mind, some advertisers have opted for real patients in campaigns instead of actors.

“Before and after” photos are a staple of advertisements for dermatological medications. These photos become more convincing if real patients are depicted. Not only does the portrayal of the true efficacy of the medication become more accurate, the authenticity of the message is enhanced.

Nervous to ditch the actors? In our pharma DTC concept testing research, patient groups evaluate different ads and rate them according to standard metrics, such as their expected likelihood of asking their doctor to prescribe the medication. Patients can often sense when an advertisement is inauthentic and the message is more likely to resonate when authenticity shines through.

 

This article is republished with permission. Click here to read the original posting.

Fred Church


May 29, 2018 0

If I have heard it once, I have heard it a thousand times: organic marketing on Facebook is dead. Pay-to-play, experts say, is the only way to really reach desired audiences. Regardless of industry, this has been the overall takeaway.

This clarion call has only gotten louder since Facebook announced in January that it would further prioritize content from friends and family on users’ News Feeds (see here for Facebook’s current commercial). This effectively makes it nearly impossible for brands’ organic content to rank high enough to be seen and forces them to spend more on paid ads.

Well, to paraphrase Mark Twain, reports of the death of organic Facebook marketing have been greatly exaggerated. The first step to successfully fighting off that organic content death knell is identifying what connects Facebook users to those friends and family whose content will be prioritized: relationship.

Relationship Required for Effective Organic AND Paid

The challenge – for brands, at least – is that Facebook feeds effectively reflect what we want to do and see in real life. As users, we are interested in what our family members are up to; get excited about friends’ baby announcements; and engage with people on their opinion about new movies.

All of these things are built around our unique relationships, and, to be blunt, reading a post from a pharmaceutical campaign doesn’t typically rise to that same level. In general, a brand’s priorities are not about the Facebook user; they’re about the brand. It’s possible for a brand to establish a trustworthy relationship with users, but it requires commitment.

What exactly do I mean when I talk about a relationship on Facebook? Despite Facebook being a technology platform, the relationships are still human. They can be emotional, educational and supportive. Ultimately, two-way conversations are the cost of entry for a true relationship.

If a brand creates content that allows for meaningful conversation and has a clear benefit to users, it will start to receive likes, comments, and shares. As that brand’s content consistently receives engagement, Facebook will increasingly deem this a real relationship and make it more likely for that content to appear organically in the feed.

Organic growth will slowly occur as people share posts with their friends, who then share the posts with their friends. Eventually, brands will begin to build relationships via these people who are connected by shared interests. For those with patience, there is power in organic growth.

Of course, for those with less patience who want to reach more people quickly, it then is necessary to pay to promote content. However, a marketer with good Facebook user relationships – and, as a result, successful organic content – won’t need to pay as much. Facebook understands the value of relationships to users, as well as the value of those relationships to the relevance of the entire platform. Therefore, it doesn’t want to waste feed real estate – no matter how much brands pay them – on poor relationships.

How Most DTC Marketing Content Falls Short

Unfortunately, pharmaceutical brands don’t necessarily have the infrastructure to create authentic, relationship-building content that truly meets patients where they are. For a multitude of reasons – including risk, regulatory issues, and the lack of a core competency in creating content – it is nearly impossible for marketers to engage in open-ended conversations via social and digital platforms, including via unbranded campaigns. This reality limits the organic potential.

Marketers of unbranded campaigns often create generic content relevant to a perceived majority of people living with a specific condition or focused around a celebrity with some relationship to that condition.

However, not every person has the same experience with a specific condition. From symptoms to family life dynamics, people are as diverse as their feeds. Regardless, pharma brands spend a lot of money and resources forcing generic content into people’s Facebook feeds that doesn’t truly foster a relationship. Making matters worse, it creates a vicious cycle of overpaying.

What Marketers Need to Do

As marketers, we need to create a range of personal content that speaks to people at various stages of their journeys. This content must encompass a wide variety of emotional, educational and comprehension levels. For example, it’s important to include posts about clinical trials for those who are more inquisitive and proactive about treatments along with lifestyle articles about how tough it can be to wake up in the morning for the newly diagnosed.

The intent behind this is not simply to increase reach, which it still does. On a greater scale, it establishes that a brand is willing to understand where people are in their patient journeys, as well as the information, resources, and conversations they need. This increases the likelihood that a Facebook user with a specific condition will find content relevant and worthy of engagement. That engagement then makes it more likely to push that marketer’s content toward the top of that user’s feed.

There are two major obstacles here. First, it’s not easy to just start creating relatable posts, engaging around it on Facebook, and assuming it will have impact as organic content. Marketers need to be fully committed to having a two-way relationship with people and everything that entails.

Second, as mentioned previously, pharmaceutical brands can only do so much on social and digital channels, due to the regulatory environment. Therefore, the first step is to get into the mindset of “meeting people where they are.” This is done by being open to and then creating promotional campaigns, tools, and ads that show the brand understands various aspects of the patient journey, as opposed to creating a single ad or promoted post that might only be relevant to a subset of people with a condition.

However, to truly get the desired organic reach on Facebook, brands should invest in the necessary resources to understand people’s needs. The best way to do this is by partnering with companies adept at listening to relevant condition-specific conversations, moderating engagement, and adapting messaging. In short, these partnerships are the relationships brands need to create and maintain meaningful relationships on Facebook.

David Shronk


May 29, 2018 0

In an ever-changing pharma environment staying connected is vital. Amidst regulatory challenges and uncertainty of new channels, the pharma industry is beginning to embrace social media to empower patients and healthcare providers. Social platforms are uniquely designed to support patient and provider needs perhaps more directly and efficiently than traditional channels. Social technologies can be leveraged to support patient engagement, ultimately leading to healthier patient outcomes.

 

Karen Weber


May 29, 2018 0

Sponsored Content

PatientPoint had the honor of sponsoring the Top 25 DTC Marketers and Hall of Fame awards at last month’s DTC National. During Hall of Fame inductee Christine Sakdalan’s passionate acceptance speech, one of her quotes really stood out, as it touched on some very relevant topics within our industry. She said: “More than ever, we have the great privilege and responsibility in healthcare to positively impact people’s lives. To make a meaningful difference in patient outcomes, we must purposefully lead with compassion and empathy, engage in relevant dialogue and foster partnership across the healthcare ecosystem.”

These values that Christine noted need to be at the forefront of decision-making during planning season. Lead with empathy. Engage in meaningful dialogue. Foster partnership. If your marketing strategy is built on these foundational tenants, and delivers relevant messaging to the patient at the time he or she needs the information the most, a positive impact is a near guarantee.

I see proof of this daily as I work with our client partners to create plans that enable their brands to be a part of the important discussions between patients and physicians. Sharing compelling testimonials, savings offers, clinical trial results and other similar information in the doctor’s office offers patients the guidance and empowerment they need at this time, making your brand a true partner to not only patients but their healthcare providers as well.

With all the news about consumers losing trust in brands today, it seems now more than ever is the time we collectively focus our efforts on what truly matters the most—the patient. This may involve a change from your tried and true marketing tactics, instead thinking outside the box to focus more on the channels, like point of care, that enable you to truly connect with patients and physicians and, as Christine so well noted in her speech, make a meaningful difference in patients’ lives. PatientPoint can help you do just that.

 

Linda Ruschau